<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052567</url>
  </required_header>
  <id_info>
    <org_study_id>CEND1-201</org_study_id>
    <nct_id>NCT05052567</nct_id>
  </id_info>
  <brief_title>CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma</brief_title>
  <official_title>Phase 1b/2 Clinical Study on Safety, Pharmacokinetics, and Preliminary Efficacy of CEND-1 for Injection in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cend Therapeutics Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the preliminary safety, efficacy and PK&#xD;
      characteristics of cend-1 in patients with advanced metastatic pancreatic ductal&#xD;
      adenocarcinoma (Chinese population).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, non-randomized, open-label phase Ib/II clinical study carried&#xD;
      out in Chinese patients with advanced metastatic pancreatic ductal adenocarcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of CEND-1 mesured by AEs, SAEs and treatment related adverse events.</measure>
    <time_frame>12 month</time_frame>
    <description>Adverse events (AEs), serious adverse events (SAEs), treatment related adverse events are included. The investigator should carry out judgment for investigational drug correlation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary efficacy of CEND-1 mesured by ORR, DOR, DCR, OS, PFS ect.</measure>
    <time_frame>12 month</time_frame>
    <description>Objective response rate (ORR), duration of response (DOR), disease control rate (DCR), overall survival (OS), progress-free survival (PFS), PFS rate, OS rate etc. are included.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>CEND-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CEND-1+paclitaxel (albumin-bound type)+gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEND-1</intervention_name>
    <description>The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine</description>
    <arm_group_label>CEND-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 to 80 years old, male or female.&#xD;
&#xD;
          -  Patients with histologically confirmed metastatic pancreatic ductal adenocarcinoma;&#xD;
&#xD;
          -  The Eastern Cooperative Oncology Group (ECOG) score is 0 to 1.&#xD;
&#xD;
          -  The life expectancy is no less than 12 weeks.&#xD;
&#xD;
          -  According to the RECIST v1.1 evaluation criteria, the patient has at least one&#xD;
             measurable lesion (exclude if there is only a target lesion located at a site&#xD;
             previously treated with radiation);&#xD;
&#xD;
          -  The patient who is suitable for first-line treatment with a combined regimen of&#xD;
             paclitaxel (albumin-bound type) and gemcitabine;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patients who have been previously treated with chemotherapy or other drugs for&#xD;
             pancreatic carcinoma, or who have been treated with other anti-cancer drugs, including&#xD;
             chemotherapy, targeted therapy, immunotherapy, or biologics.&#xD;
&#xD;
          -  The patients who are known to be allergic to the investigatinal drug (CEND-1 analogue)&#xD;
             or its any excipient;&#xD;
&#xD;
          -  The patients with the following conditions: myocardial infarction, severe/unstable&#xD;
             angina, NYHA grade 2 or above cardiac dysfunction, and clinically significant&#xD;
             supraventricular or ventricular arrhythmia requiring clinical intervention within 6&#xD;
             months before signing the ICF;&#xD;
&#xD;
          -  The patients with symptomatic CNS metastasis, leptomeningeal metastases, or spinal&#xD;
             cord compression due to metastasis. However, the patients with symptomatic CNS&#xD;
             metastasis before first administration of the investigational drug, who is treated and&#xD;
             stable for no less than 4 weeks, and the systematic hormone (any dose) treatment has&#xD;
             been stopped for over 2 weeks, can be enrolled;&#xD;
&#xD;
          -  The patients with other active malignant tumors within 3 years before signing the ICF.&#xD;
             The cured skin basal cell carcinoma or squamous cell carcinoma, superficial bladder&#xD;
             cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast ductal, and&#xD;
             papillary thyroid cancer are excluded.&#xD;
&#xD;
          -  The patients with human immunodeficiency virus (HIV) infection or known acquired&#xD;
             immunodeficiency syndrome (AIDS), active hepatitis or co-infection with hepatitis B&#xD;
             and C.&#xD;
&#xD;
          -  The patients who participated in any other drug clinical trial and administrated the&#xD;
             investigational drug within 4 weeks before first dose;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

